|Anavex Life Sciences Corp -- USA Stock|| |
USD 3.69 0.49 15.31%
VP of Preclinical OperationsWe currently do not have informatin regarding Ulrich Elben. This executive tanure with Anavex Life Sciences Corp is not currenlty determined.
The company has return on total asset (ROA)
of (56.16) %
which means that it has lost $56.16 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (95.21) %
meaning that it created substantial loss on money invested by shareholders.
Anavex Life Sciences Corporation, a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer?s disease, other central nervous system diseases, pain, and various cancers. Anavex Life Sciences Corp (AVXL) is traded on Nasdaq Capital Markets in USA. It is located in NEW YORK, U.S.A and employs 10 people. Anavex Life is listed under Business Services category by Fama And French industry classification.